Pasithea Therapeutics Corp.
KTTAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframePasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and. At a $15.2M market cap, Pasithea Therapeutics Corp. ranks as a micro-cap company within healthcare. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis.
Market Cap
$15.2M
Beta
0.29
P/E (TTM)
—
P/E (Fwd)
-0.45
EPS (TTM)
$-1.36
EPS (Fwd)
$-1.01
ROE
-58.2%
ROA
-31.5%
Cash
$50.4M
Total Debt
$0
Free CF
-$11.8M
52W Change
-36.8%
Annual Financials
Cash vs Debt
Where KTTA stands vs its 150-day and 200-day moving averages
As of the July 15, 2026 close, KTTA finished 39.24% below its 150-day moving average ($0.79) and 39.24% below its 200-day moving average ($0.79). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is KTTA overbought or oversold?
At the July 15, 2026 close, KTTA's RSI(14) was 27.6, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Pasithea Therapeutics Corp. reports $50.4M in cash and $0 in total debt. The company is burning cash, with free cash flow at -$11.8M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -58.2% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
KTTA's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Pasithea Therapeutics Corp. and its sector.